{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:55:59Z","timestamp":1780617359212,"version":"3.54.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1157\/13127088","type":"journal-article","created":{"date-parts":[[2008,10,23]],"date-time":"2008-10-23T02:28:16Z","timestamp":1224728896000},"page":"477-484","source":"Crossref","is-referenced-by-count":22,"title":["Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study"],"prefix":"10.1016","volume":"31","author":[{"given":"Javier P.","family":"Gisbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Gonz\u00e1lez-Lama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s D.","family":"Pousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Moreno-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Mat\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1157\/13127088_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","author":"Sutherland","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1157\/13127088_bb0015","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1017987229718","article-title":"Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review","volume":"47","author":"Gisbert","year":"2002","journal-title":"Dig Dis Sci"},{"key":"10.1157\/13127088_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2036.2000.00683.x","article-title":"Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease","volume":"14","author":"Corrigan","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.0269-2813.2004.01827.x","article-title":"Systematic review: shortterm adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis","volume":"19","author":"Loftus","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0030","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ibd.20099","article-title":"5-aminosalicylates and renal function in inflammatory bowel disease: a systematic review","volume":"13","author":"Gisbert","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1157\/13127088_bb0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/bmj.1.5793.152","article-title":"Nephrotoxic lesions from 5-aminosalicylic acid","volume":"1","author":"Calder","year":"1972","journal-title":"Br Med J"},{"issue":"Suppl","key":"10.1157\/13127088_bb0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/00365529009091911","article-title":"Mesalazine: an overview of key preclinical studies","volume":"172","author":"Bilyard","year":"1990","journal-title":"Scand J Gastroenterol"},{"key":"10.1157\/13127088_bb0045","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/oxfordjournals.ndt.a027349","article-title":"Mesalazineassociated interstitial nephritis","volume":"11","author":"World","year":"1996","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl:2-6","key":"10.1157\/13127088_bb0050","article-title":"Classification of inflammatory bowel disease","volume":"170","author":"Lennard-Jones","year":"1989","journal-title":"Scand J Gastroenterol"},{"key":"10.1157\/13127088_bb0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1157\/13127088_bb0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/bmj.38975.390370.7C","article-title":"How to measure renal function in clinical practice","volume":"333","author":"Traynor","year":"2006","journal-title":"BMJ"},{"key":"10.1157\/13127088_bb0065","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/00042737-199511000-00003","article-title":"Comparison of the efficacy and safety of 1.5 compared with 3.0g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group [see comments]","volume":"7","author":"Fockens","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1157\/13127088_bb0070","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1046\/j.1365-2036.1996.92264000.x","article-title":"Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France","volume":"10","author":"Marteau","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0075","first-page":"816","article-title":"5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis","volume":"92","author":"Walker","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13127088_bb0080","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/gut.51.4.536","article-title":"Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines","volume":"51","author":"Ransford","year":"2002","journal-title":"Gut"},{"key":"10.1157\/13127088_bb0085","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2036.2002.01216.x","article-title":"Review article: monitoring for drug side-effects in inflammatory bowel disease","volume":"16","author":"Cunliffe","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0090","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1136\/gut.52.10.1530","article-title":"Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines","volume":"52","author":"Logan","year":"2003","journal-title":"Gut"},{"key":"10.1157\/13127088_bb0095","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1053\/j.gastro.2004.03.016","article-title":"5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study","volume":"126","author":"Van Staa","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1157\/13127088_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5414\/CNP61083","article-title":"Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?","volume":"61","author":"Elseviers","year":"2004","journal-title":"Clin Nephrol"},{"key":"10.1157\/13127088_bb0105","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2036.2005.02462.x","article-title":"Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom","volume":"21","author":"Muller","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0110","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1136\/gut.33.10.1348","article-title":"Tests of renal function in patients with quiescent colitis: effects of drug treatment","volume":"33","author":"Riley","year":"1992","journal-title":"Gut"},{"key":"10.1157\/13127088_bb0115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00054725-200011000-00003","article-title":"Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis","volume":"6","author":"Birketvedt","year":"2000","journal-title":"Inflamm Bowel Dis"},{"key":"10.1157\/13127088_bb0120","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/0140-6736(92)91601-4","article-title":"Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis [see comments]","volume":"339","author":"Courtney","year":"1992","journal-title":"Lancet"},{"key":"10.1157\/13127088_bb0125","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.MIB.0000185402.65288.19","article-title":"5- Aminosalicylates and effects on renal function in patients with Crohn's disease","volume":"11","author":"De Jong","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1157\/13127088_bb0130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF00505331","article-title":"Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man","volume":"326","author":"Diener","year":"1984","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1157\/13127088_bb0135","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1046\/j.1365-2036.2001.01041.x","article-title":"Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy","volume":"15","author":"Fraser","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0140","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0016-5085(93)90411-5","article-title":"Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d\u2019Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID) [see comments]","volume":"104","author":"Gendre","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1157\/13127088_bb0145","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2036.1992.tb00561.x","article-title":"Improved maintenance of remission in ulcerative colitis by balsalazide 4g\/day compared with 2g\/day","volume":"6","author":"Giaffer","year":"1992","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0150","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2036.1992.tb00578.x","article-title":"Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months","volume":"6","author":"Green","year":"1992","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0155","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1046\/j.1365-2036.1998.00427.x","article-title":"Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator Group","volume":"12","author":"Green","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0160","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1053\/gast.1997.v112.pm9041232","article-title":"A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group for Ulcerative Colitis","volume":"112","author":"Hawkey","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1157\/13127088_bb0165","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/gut.29.6.835","article-title":"Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis","volume":"29","author":"Ireland","year":"1988","journal-title":"Gut"},{"key":"10.1157\/13127088_bb0170","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/gut.33.2.252","article-title":"Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group","volume":"33","author":"Kiilerich","year":"1992","journal-title":"Gut"},{"key":"10.1157\/13127088_bb0175","first-page":"391","article-title":"Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis","volume":"7","author":"Kruis","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1157\/13127088_bb0180","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1365-2036.2002.01155.x","article-title":"Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis","volume":"16","author":"Mahmud","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2036.1988.tb00693.x","article-title":"Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine","volume":"2","author":"McIntyre","year":"1988","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0190","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7326\/0003-4819-124-2-199601150-00003","article-title":"A randomized, placebo-controlled trial. The Mesalamine Study Group [see comments]","volume":"124","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1157\/13127088_bb0195","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/ndt\/15.4.498","article-title":"Altered IgG(4) renal clearance in patients with inflammatory bowel diseases. Evidence for a subclinical impairment of protein charge renal selectivity","volume":"15","author":"Monteleone","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1157\/13127088_bb0200","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0016-5085(88)80061-1","article-title":"Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis [see comments]","volume":"95","author":"Mulder","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1157\/13127088_bb0205","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3748\/wjg.v12.i5.739","article-title":"Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?","volume":"12","author":"Poulou","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1157\/13127088_bb0210","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","article-title":"Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial","volume":"298","author":"Rachmilewitz","year":"1989","journal-title":"BMJ"},{"key":"10.1157\/13127088_bb0215","first-page":"438","article-title":"Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double- blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group","volume":"87","author":"Rijk","year":"1992","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13127088_bb0220","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/gut.29.5.669","article-title":"Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse","volume":"29","author":"Riley","year":"1988","journal-title":"Gut"},{"key":"10.1157\/13127088_bb0225","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/0016-5085(88)90677-4","article-title":"Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis","volume":"94","author":"Riley","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1157\/13127088_bb0230","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2036.1989.tb00204.x","article-title":"Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group","volume":"3","author":"Rutgeerts","year":"1989","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0235","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/0016-5085(86)90882-6","article-title":"Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse- prevention properties","volume":"90","author":"Sandberg-Gertzen","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1157\/13127088_bb0240","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gut.40.6.761","article-title":"Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate","volume":"40","author":"Schreiber","year":"1997","journal-title":"Gut"},{"key":"10.1157\/13127088_bb0245","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1157\/13127088_bb0250","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-C","article-title":"Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group [see comments]","volume":"104","author":"Singleton","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1157\/13127088_bb0255","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1572-0241.2005.t01-5-41219.x","article-title":"5-ASA therapy and renal function in inflammatory bowel disease","volume":"100","author":"Siveke","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13127088_bb0260","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2036.1995.tb00438.x","article-title":"Mesalazine (Mesasal\/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease","volume":"9","author":"Thomson","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13127088_bb0265","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000013480","article-title":"Chronic interstitial nephritis due to 5-aminosalicylic acid","volume":"19","author":"Agharazii","year":"1999","journal-title":"Am J Nephrol"},{"key":"10.1157\/13127088_bb0270","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s00467-004-1411-6","article-title":"Interstitial nephritis from mesalazine: case report and literature review","volume":"19","author":"Arend","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1157\/13127088_bb0275","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-2007-1025324","article-title":"Chronic inflammatory intestinal disease and nephritis","volume":"204","author":"Behrens","year":"1992","journal-title":"Klin Padiatr"},{"key":"10.1157\/13127088_bb0280","first-page":"199","article-title":"[Renal involvement in patients with chronic inflammatory intestinal disease treated with mesalazine. How to prevent its nephrotoxicity?] [letter]","volume":"113","author":"Bonet","year":"1999","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13127088_bb0285","first-page":"724","article-title":"Chronic interstitial nephritis and mesalazine: 3 new cases?","volume":"22","author":"Brouillard","year":"1998","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1157\/13127088_bb0290","first-page":"265","article-title":"Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease","volume":"49","author":"Calvino","year":"1998","journal-title":"Clin Nephrol"},{"key":"10.1157\/13127088_bb0295","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(94)92009-5","article-title":"Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? [letter] [see comments]","volume":"344","author":"Colombel","year":"1994","journal-title":"Lancet"},{"key":"10.1157\/13127088_bb0300","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/ndt\/12.9.1839","article-title":"5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?","volume":"12","author":"De Broe","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1157\/13127088_bb0305","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004836-199701000-00008","article-title":"Nephrotic syndrome from 5-ASA for ulcerative colitis? Complicated by carcinoma of the colon and sclerosing cholangitis","volume":"24","author":"Fornaciari","year":"1997","journal-title":"J Clin Gastroenterol"},{"key":"10.1157\/13127088_bb0310","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000064461","article-title":"Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease","volume":"92","author":"Frandsen","year":"2002","journal-title":"Nephron"},{"key":"10.1157\/13127088_bb0315","first-page":"18","article-title":"[Acute renal failure associated with 5-aminosalicylic acid in inflammatory bowel disease]","volume":"18","author":"Garc\u00eda-D\u00edaz","year":"1995","journal-title":"Gastroenterol Hepatol"},{"key":"10.1157\/13127088_bb0320","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/ajkd.2001.25216","article-title":"Acute renal failure in a 53-year-old woman with Crohn's disease treated with 5-aminosalicylic acid","volume":"38","author":"Haas","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1157\/13127088_bb0325","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000201459","article-title":"5-Aminosalicylic acid-associated renal tubular acidosis with decreased renal function in Crohn's disease","volume":"58","author":"Hamling","year":"1997","journal-title":"Digestion"},{"key":"10.1157\/13127088_bb0330","first-page":"1091","article-title":"[Chronic interstitial nephritis after treatment with 5-aminosalicylic acid]","volume":"114","author":"Henning","year":"1989","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1157\/13127088_bb0335","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1445-5994.1998.tb01962.x","article-title":"Renal dysfunction and the treatment of inflammatory bowel disease (IBD): a case for monitoring","volume":"28","author":"Howard","year":"1998","journal-title":"Aust N Z J Med"},{"key":"10.1157\/13127088_bb0340","first-page":"343","article-title":"Chronic interstitial nephritis induced by 5-aminosalicylic acid: a new case report","volume":"23","author":"Laboudi","year":"2002","journal-title":"Nephrologie"},{"key":"10.1157\/13127088_bb0345","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2169\/naika.90.872","article-title":"[Interstitial nephritis after treatment with mesalazine in the patient with ulcerative colitis]","volume":"90","author":"Maeda","year":"2001","journal-title":"Nippon Naika Gakkai Zasshi"},{"key":"10.1157\/13127088_bb0350","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/oxfordjournals.ndt.a027787","article-title":"Mesalazine-associated interstitial nephritis: twice in the same patient","volume":"12","author":"Manenti","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1157\/13127088_bb0355","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00004836-200102000-00019","article-title":"Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine","volume":"32","author":"Margetts","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"10.1157\/13127088_bb0360","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/gut.33.4.563","article-title":"Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss","volume":"33","author":"Masson","year":"1992","journal-title":"Gut"},{"key":"10.1157\/13127088_bb0365","first-page":"1031","article-title":"Acute interstitial nephritis due to 5-aminosalicylic acid","volume":"143","author":"Mehta","year":"1990","journal-title":"CMAJ"},{"key":"10.1157\/13127088_bb0370","first-page":"728","article-title":"Early renal failure caused by mesalazine","volume":"46","author":"Musil","year":"2000","journal-title":"Vnitr Lek"},{"key":"10.1157\/13127088_bb0375","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/bmj.296.6634.1442","article-title":"Nephrotic syndrome after treatment with 5-aminosalicylic acid","volume":"296","author":"Novis","year":"1988","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1157\/13127088_bb0380","first-page":"414","article-title":"[Interstitial nephritis induced by mesalazine]","volume":"44","author":"Ohya","year":"2002","journal-title":"Nippon Jinzo Gakkai Shi"},{"key":"10.1157\/13127088_bb0385","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/bmj.317.7161.795","article-title":"Late onset interstitial nephritis associated with mesalazine treatment","volume":"317","author":"Popoola","year":"1998","journal-title":"BMJ"},{"key":"10.1157\/13127088_bb0390","first-page":"262","article-title":"Acute interstitial nephritis caused by 5-aminosalicylic acid?","volume":"30","author":"Ruf-Ballauf","year":"1989","journal-title":"Internist (Berl)"},{"key":"10.1157\/13127088_bb0395","first-page":"2557","article-title":"Tubulointerstitial nephritis caused by mesalazine (5-ASA) agents","volume":"138","author":"Smilde","year":"1994","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1157\/13127088_bb0400","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1440-1797.2005.00376.x","article-title":"Acute interstitial nephritis due to mesalazine","volume":"10","author":"Tadic","year":"2005","journal-title":"Nephrology (Carlton)"},{"key":"10.1157\/13127088_bb0405","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/gut.35.10.1493","article-title":"Mesalazine induced interstitial nephritis","volume":"35","author":"Thuluvath","year":"1994","journal-title":"Gut"},{"key":"10.1157\/13127088_bb0410","first-page":"236","article-title":"[Nephritis from 5-aminosalicylic acid]","volume":"114","author":"von Muhlendahl","year":"1989","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1157\/13127088_bb0415","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0002-9343(97)89466-1","article-title":"Nephrotoxicity associated with olsalazine","volume":"100","author":"Wilcox","year":"1996","journal-title":"Am J Med"},{"key":"10.1157\/13127088_bb0420","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000188024","article-title":"Interstitial nephritis associated with 5-aminosalicylic acid","volume":"67","author":"Witte","year":"1994","journal-title":"Nephron"},{"key":"10.1157\/13127088_bb0425","first-page":"461","article-title":"Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease","volume":"8","author":"Kreisel","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1157\/13127088_bb0430","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1258\/0004563001901434","article-title":"Creatinine clearance and glomerular filtration rate","volume":"37","author":"Payne","year":"2000","journal-title":"Ann Clin Biochem"},{"key":"10.1157\/13127088_bb0435","first-page":"88","article-title":"What can nephrologists learn from epidemiology?","volume":"14","author":"Elseviers","year":"2001","journal-title":"J Nephrol"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570508759557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570508759557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T17:40:09Z","timestamp":1557855609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570508759557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0210570508759557"],"URL":"https:\/\/doi.org\/10.1157\/13127088","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1138882.595975","asserted-by":"object"}]},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}